Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 11/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211290 | 0.90 | HDAC1 (0.49) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211858 | 0.90 | HDAC1 (0.49) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211292 | 0.90 | HDAC1 (0.49) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211284 | 0.90 | HDAC1 (0.54) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211299 | 0.89 | HDAC6 (0.54) | HDAC1HDAC6HDAC8HDAC5MAPT | |
| SCHEMBL16211327 | 0.89 | HDAC6 (0.53) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211581 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16221530 | 0.88 | HDAC6 (0.52) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL16211302 | 0.88 | HDAC1 (0.66) | HDAC1HDAC6HDAC8HDAC5POLB | |
| SCHEMBL22218368 | 0.87 | HDAC1 (0.51) | HDAC1HDAC6HDAC8HDAC5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.